Literature DB >> 1776971

Sympathetic stimulation-evoked overflow of norepinephrine and neuropeptide Y from the heart.

M R Warner1, P D Senanayake, C M Ferrario, M N Levy.   

Abstract

Neuropeptide Y (NPY) and norepinephrine are released together on sympathetic activation. To compare the time courses of NPY and norepinephrine washout from cardiac tissues, we measured the overflow of NPY-like immunoreactivity (NPY-LI) and norepinephrine in coronary sinus blood before, during, and after 3-minute trains of ansae subclaviae stimulation in 13 anesthetized dogs. We also measured vagally induced cardiac cycle length responses before and after ansae stimulation. Ansae stimulation increased NPY-LI and norepinephrine overflow from the heart in a frequency-dependent manner (p less than 0.02). After stimulation of the ansae at 5 and 10 Hz, the peak norepinephrine overflows decayed by 90% within 2 minutes, but the NPY-LI overflows required 17 +/- 11 and 35 +/- 21 minutes, respectively, to decay by 90%. Cardiac vagal effects were inhibited after 5- and 10-Hz ansae stimulations, and the peak inhibitions decayed by 90% after 19 +/- 7 and 39 +/- 16 minutes, respectively. The 90% decay times of the NPY-LI overflows were longer (p less than 0.003) than those of the norepinephrine overflows but did not differ significantly (p greater than 0.4) from the 90% decay times of the inhibition of vagal effects. We characterized NPY-LI in coronary sinus and arterial plasma by reversed-phase high-performance liquid chromatography. Before ansae stimulation, the main peak of NPY-LI in the plasma had a retention time similar to that of the oxidized human NPY-(1-36) standard. During ansae stimulation, however, there was a substantial increase in the peak of NPY-LI that eluted in a position similar to that of the monoxidized human NPY-(1-36) standard. These data support the hypothesis that neurally released NPY mediates the sympathetically evoked inhibition of vagal effects and indicate that the time course of removal of NPY from the heart differs substantially from that of norepinephrine. Moreover, under basal conditions, most NPY in the circulation is present in the oxidized form or as a fragment of the 36-amino-acid peptide. In contrast, cardiac sympathetic stimulation evokes the overflow of monoxidized NPY-(1-36) into the coronary sinus plasma.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1776971     DOI: 10.1161/01.res.69.2.455

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  11 in total

Review 1.  Dynamic nonlinear vago-sympathetic interaction in regulating heart rate.

Authors:  K Sunagawa; T Kawada; T Nakahara
Journal:  Heart Vessels       Date:  1998       Impact factor: 2.037

2.  Role of neuropeptide Y and peroxisome proliferator-activated receptor γ coactivator-1α in stress cardiomyopathy.

Authors:  Sunnassee Ananda; Yunyun Wang; Shaohua Zhu; Rongshuai Wang; Xiaowei Zhou; Luo Zhuo; Tingyi Sun; Liang Ren; Qian Liu; Hongmei Dong; Yan Liu; Liang Liu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-12-28

Review 3.  Peripheral cardiac sympathetic hyperactivity in cardiovascular disease: role of neuropeptides.

Authors:  Julia Shanks; Neil Herring
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-09-04       Impact factor: 3.619

4.  NPY1-36 and PYY1-36 activate cardiac fibroblasts: an effect enhanced by genetic hypertension and inhibition of dipeptidyl peptidase 4.

Authors:  Xiao Zhu; Delbert G Gillespie; Edwin K Jackson
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-09-14       Impact factor: 4.733

Review 5.  Regulation of geminin by neuropeptide Y in vascular smooth muscle cell proliferation : A current review.

Authors:  S-Y Liang; Y-L Zhou; M-Q Shu; S Lin
Journal:  Herz       Date:  2018-08-27       Impact factor: 1.443

Review 6.  Mechanisms underlying the autonomic modulation of ventricular fibrillation initiation--tentative prophylactic properties of vagus nerve stimulation on malignant arrhythmias in heart failure.

Authors:  Kieran E Brack; James Winter; G André Ng
Journal:  Heart Fail Rev       Date:  2013-07       Impact factor: 4.214

7.  The cardiac sympathetic co-transmitter galanin reduces acetylcholine release and vagal bradycardia: implications for neural control of cardiac excitability.

Authors:  Neil Herring; James Cranley; Michael N Lokale; Dan Li; Julia Shanks; Eric N Alston; Beatrice M Girard; Emma Carter; Rodney L Parsons; Beth A Habecker; David J Paterson
Journal:  J Mol Cell Cardiol       Date:  2011-12-07       Impact factor: 5.000

Review 8.  Autonomic control of the heart: going beyond the classical neurotransmitters.

Authors:  Neil Herring
Journal:  Exp Physiol       Date:  2014-11-20       Impact factor: 2.969

9.  Neuropeptide-Y causes coronary microvascular constriction and is associated with reduced ejection fraction following ST-elevation myocardial infarction.

Authors:  Neil Herring; Nidi Tapoulal; Manish Kalla; Xi Ye; Lyudmyla Borysova; Regent Lee; Erica Dall'Armellina; Christopher Stanley; Raimondo Ascione; Chieh-Ju Lu; Adrian P Banning; Robin P Choudhury; Stefan Neubauer; Kim Dora; Rajesh K Kharbanda; Keith M Channon
Journal:  Eur Heart J       Date:  2019-06-21       Impact factor: 29.983

10.  Rapid measurement of cardiac neuropeptide dynamics by capacitive immunoprobe in the porcine heart.

Authors:  Nicholas Kluge; Michael Dacey; Joseph Hadaya; Kalyanam Shivkumar; Shyue-An Chan; Jeffrey L Ardell; Corey Smith
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-10-23       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.